Alterations in the Smad pathway in human cancers

Frontiers in Bioscience

Volumn 17, Issue 4, 2012, Pages 1281-1293

  Samanta, Debangshu ^b   Datta, Pran K ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cancer; Neoplasia; Review; Smads; TGF ; Tumor

Indexed keywords

ANIMALIA;

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CHEMICAL STRUCTURE; DRUG ANTAGONISM; HUMAN; METABOLISM; MOUSE; NEOPLASM; REVIEW; UPREGULATION;

ANIMALS; HUMANS; MICE; MODELS, MOLECULAR; NEOPLASMS; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84859259668     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3986     Document Type: Review

References (125)

1. Gray, A. M. & Mason, A. J. Requirement for activin A and transforming growth factor-β1 pro-regions in homodimer assembly. Science 247, 1328-1330 (1990).
2. Shimmi, O., Umulis, D., Othmer, H. & O'Connor, M. B. Facilitated transport of a Dpp/Scw heterodimer by Sog/Tsg leads to robust patterning of the Drosophila blastoderm embryo. Cell 120, 873-886 (2005). (Pubitemid 40568802)
3. Dubois, C. M., Laprise, M. H., Blanchette, F., Gentry, L. E. & Leduc, R. Processing of transforming growth factor β1 precursor by human furin convertase. J. Biol. Chem. 270, 10618-10624 (1995).
4. Constam, D. B. & Robertson, E. J. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J. Cell Biol. 144, 139-149 (1999). (Pubitemid 29047017)
5. Annes, J. P., Munger, J. S. & Rifkin, D. B. Making sense of latent TGF-beta activation. J. Cell Sci. 116, 217- 224 (2003). (Pubitemid 36163863)
6. Ge, G. & Greenspan, D. S. BMP1 controls TGFβ1 activation via cleavage of latent TGFβ-binding protein. J. Cell Biol. 175, 111-120 (2006). (Pubitemid 44537203)
7. Ben-Haim N, Lu C, Guzman-Ayala M, Pescatore L, Mesnard D, Bischofberger M, Naef F, Robertson EJ, Constam DB.The nodal precursor acting via activin receptors induces mesoderm by maintaining a source of its convertases and BMP4. Dev. Cell 11, 313-323 (2006). (Pubitemid 44283943)
8. Shi, Y. & Massagué, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685- 700 (2003). (Pubitemid 36724933)
9. Yeo, C. & Whitman, M. Nodal signals to SMADs through Cripto-dependent and Cripto-independentmechanisms. Mol. Cell 7, 949-957 (2001). (Pubitemid 32525742)
10. Massagué, J. How cells read TGF-beta signals. Nature Rev. Mol. Cell Biol. 1, 169-178 (2000).
11. Itoh, S., Itoh, F., Goumans, M. J. & ten Dijke, P. Signaling of transforming growth factor-b familymembers through Smad proteins. Eur. J. Biochem. 267, 6954-6967 (2000). (Pubitemid 32009435)
12. Moustakas, A., Souchelnytskyi, S. & Heldin, C.-H. Smad regulation in TGF-beta signal transduction. J. Cell Sci. 114, 4359-4369 (2001). (Pubitemid 34082857)
13. Wrana, J.L., Attisano, L., Wieser, R., Ventura, F. & Massagué, J. Mechanism of activation of the TGF-beta receptor. Nature 370, 341-347. (1994). (Pubitemid 2110860)
14. Heldin, C.-H., Miyazono, K. & ten Dijke, P. TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471. (1997). (Pubitemid 28013118)
15. Kirsch, T., Sebald, W. & Dreyer, M.K. Crystal structure of the BMP-2-BRIA ectodomain complex. Nature Struct. Biol. 7, 492-496. (2000). (Pubitemid 30414472)
16. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276, 12477-12480. (2001).
17. Piek, E., Heldin, C.H. & ten Dijke, P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 13, 2105-2124 (1999).
18. Massagué, J., Blain, S.W. & Lo, R.S. TGF-beta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309 (2000).
19. Miyazono, K., ten Dijke, P. & Heldin, C.H. TGF-beta signaling by Smad proteins. Adv. Immunol. 75, 115-157 (2000). Review.
20. Derynck, R., Zhang, Y. & Feng, X.-H. Smads: transcriptional activators of TGF-beta responses. Cell 95, 737-740 (1998).
21. Massagué, J. & Wotton, D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J. 19, 1745- 1754 (2000). (Pubitemid 30204386)
22. Kretzschmar, M., Doody, J. & Massagué, J. Opposing BMP and EGF signaling pathway converge on the TGFbeta family mediator SMAD1. Nature 389, 618-622 (1997). (Pubitemid 27446181)
23. Kretzschmar, M., Doody, J., Timokhina, I. & Massagué, J. A mechanism of repression of TGF- β/SMAD signaling by oncogenic ras. Genes Dev. 13, 804-816 (1999). (Pubitemid 29169840)
24. Zhu, H., Kavsak, P., Abdollah, S., Wrana, J. L. & Thomsen, G. H. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400, 687-693 (1999).
25. Attisano, L., and Wrana, J. L. Mads and Smads in TGF-beta signaling. Curr. Opin. Cell Biol. 10, 188-194. (1998).
26. Yagi K, Goto D, Hamamoto T, Takenoshita S, Kato M, Miyazono K. Alternatively spliced variant of SMAD2 lacking exon 3. Comparison with wild-type SMAD2 and SMAD3. J. Biol. Chem. 274, 703-709 (1999).
27. Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L. & Wrana, J. L. SARA, a FYVE domain protein that recruits SMAD2 to the TGF-beta receptor. Cell 95, 779-791 (1998). (Pubitemid 29014458)
28. Lo, R. S., Chen, Y. G., Shi, Y. G., Pavletich, N. & Massagué, J. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-beta receptors. EMBO J. 17, 996- 1005 (1998). (Pubitemid 28077654)
29. Graff, J. M., Bansal, A. & Melton, D. A. Xenopus Mad proteins transduce distinct subsets of signals for the TGF-beta superfamily. Cell 85, 479-487 (1996). (Pubitemid 26157187)
30. Kim, J., Johnson, K., Chen, H. J., Carroll, S. & Laughon, A. Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic. Nature 388, 304-308 (1997). (Pubitemid 27317978)
31. Liu F, Hata A, Baker JC, Doody J, Cárcamo J, Harland RM, Massagué J. A human Mad protein acting as a BMPregulated transcriptional activator. Nature 381, 620-623 (1996). (Pubitemid 26177480)
32. Maliekal TT, Antony ML, Nair A, Paulmurugan R, Karunagaran D. Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer. Oncogene 22, 4889-97 (2003). (Pubitemid 36981278)
33. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 18, 4879-83 (1999). (Pubitemid 29423571)
34. Fukushima T, Mashiko M, Takita K, Otake T, Endo Y, Sekikawa K, Takenoshita S. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer. J Exp Clin Cancer Res 22, 315-20 (2003). (Pubitemid 36734191)
35. Uchida K, Nagatake M, Osada H, Yatabe Y, Kondo M, Mitsudomi T, Masuda A, Takahashi T, Takahashi T. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 56, 5583-5(1996). (Pubitemid 26422155)
36. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86, 543-52 (1996). (Pubitemid 26299486)
37. Takagi Y, Koumura H, Futamura M, Aoki S, Ymaguchi K, Kida H, Tanemura H, Shimokawa K, Saji S. Somatic alterations of the SMAD-2 gene in human colorectal cancers. Br J Cancer 78, 1152-5 (1998). (Pubitemid 28479142)
38. Prunier C, Mazars A, Noë V, Bruyneel E, Mareel M, Gespach C, Atfi A. Evidence that Smad2 is a tumor suppressor implicated in the control of cellular invasion. J Biol Chem 274, 22919-22 (1999).
39. Prunier C, Ferrand N, Frottier B, Pessah M, Atfi A. Mechanism for mutational inactivation of the tumor suppressor Smad2. Mol Cell Biol 21, 3302-13 (2001). (Pubitemid 32381766)
40. Hata A, Lo RS, Wotton D, Lagna G, Massagué J. Mutations increasing autoinhibition inactivate tumor suppressors Smad2 and Smad4. Nature 388, 82-7 (1997). (Pubitemid 27283893)
41. Prunier C, Ferrand N, Frottier B, Pessah M, Atfi A. Mechanism for mutational inactivation of the tumor suppressor Smad2. Mol Cell Biol 21, 3302-13 (2001). (Pubitemid 32381766)
42. Kretschmer A, Moepert K, Dames S, Sternberger M, Kaufmann J, Klippel A.. Differential regulation of TGFbeta signaling through Smad2, Smad3 and Smad4. Oncogene 22, 6748-6763 (2003). (Pubitemid 37372215)
43. Tian F, DaCosta Byfield S, Parks WT, Yoo S, Felici A, Tang B, Piek E, Wakefield LM, Roberts AB. Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 63(23), 8284-92 (2003). (Pubitemid 37549480)
44. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 393, 786-790 (1998). (Pubitemid 28299489)
45. Heyer J, Escalante-Alcalde D, Lia M, Boettinger E, Edelmann W, Stewart CL, Kucherlapati R. Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis. Proc Natl Acad Sci USA 96, 12595-12600.( 1999). (Pubitemid 29513547)
46. Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ. Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. Cell 92, 797-808 (1998). (Pubitemid 28155318)
47. Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX. Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc Natl Acad Sci USA 95, 9378-9383 (1998).
48. Datto MB, Frederick JP, Pan L, Borton AJ, Zhuang Y, Wang XF. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta mediated signal transduction. Mol Cell Biol 19, 2495- 2504.( 1999). (Pubitemid 29144493)
49. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng C, Kucherlapati R, Bottinger EP, Roberts AB.. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3- deficient fibroblasts. J Biol Chem 276, 19945- 19953(2001).
50. Vijayachandra K, Lee J, Glick AB. Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. Cancer Res 63, 3447-3452. (2003). (Pubitemid 36793018)
51. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine & Growth Factor Reviews 17, 41-58 (2006). (Pubitemid 43117515)
52. Chambers RC, Leoni P, Kaminski N, Laurent GJ, Heller RA. Global expression profiling of fibroblast responses to transforming growth factor-beta1 reveals the induction of inhibitor of differentiation-1 and provides evidence of smooth muscle cell phenotypic switching. Am J Pathol 162(2), 533-46 (2003). (Pubitemid 36267860)
53. Xu G, Chakraborty C, Lala PK. Reconstitution of Smad3 restores TGF-beta response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells. Biochem Biophys Res Commun 300(2), 383-90 (2003). (Pubitemid 38375820)
54. Zhu Y, Richardson JA, Parada LF, Graff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94, 703-714(1998). (Pubitemid 28436003)
55. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H, Roberts AB, Deng C.. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 18, 1280-1291(1999). (Pubitemid 29110312)
56. Maggio-Price L, Treuting P, Zeng W, Tsang M, Bielefeldt- Ohmann H, Iritani BM. Helicobacter infection is required for inflammation and colon cancer in smad3- deficient mice. Cancer Res 66, 828-838 (2006). (Pubitemid 43165948)
57. Ashcroft GS, Yang X, Glick AB, Weinstein M, Letterio JL, Mizel DE, Anzano M, Greenwell-Wild T, Wahl SM, Deng C, Roberts AB. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1, 260-266 (1999). (Pubitemid 129495775)
58. Flanders KC, Sullivan CD, Fujii M, Sowers A, Anzano MA, Arabshahi A, Major C, Deng C, Russo A, Mitchell JB, Roberts AB. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 160, 1057-1068 (2002). (Pubitemid 34224592)
59. Yanagisawa K, Osada H, Masuda A, Kondo M, Saito T, Yatabe Y, Takagi K, Takahashi T. Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene 17, 1743-1747 (1998). (Pubitemid 28482652)
60. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-52 (1998). (Pubitemid 28063364)
61. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Tahara E, Ide T, Ishikawa F. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18, 65-8 (1998). (Pubitemid 28027882)
62. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8, 279-82 (1998). (Pubitemid 28111458)
63. Wen J, Cong YS, Bacchetti S. Reconstitution of wildtype or mutant telomerase activity in telomerase- negative immortal human cells. Hum Mol Genet 7, 1137-41 (1998). (Pubitemid 28306879)
64. Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp PM, Sedivy JM, Weinberg RA. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 95, 14723-8 (1998). (Pubitemid 29003697)
65. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumor cells with defined genetic elements. Nature 400, 464-8 (1999). (Pubitemid 29361801)
66. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA. Telomerase contributes to tumorigenesis by a telomere lengthindependent mechanism. Proc Natl Acad Sci U S A 99, 12606-11(2002).
67. Lacerte A, Korah J, Roy M, Yang XJ, Lemay S, Lebrun JJ. Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors. Cellular Signaling 20 (1), 50-59 (2008). (Pubitemid 350138369)
68. Hahn SA, Seymour AB, Hoque AT, Schutte M, da Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ. Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 55, 4670-5 (1995).
69. Thiagalingam S, Lengauer C, Leach F Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 13, 343-6 (1996). (Pubitemid 26230501)
70. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 306, 799-804 (2003). (Pubitemid 36776201)
71. Massagué, J., Blain, S.W. & Lo, R.S. TGF-beta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309 (2000).
72. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350- 353 (1996).
73. Xu X, Brodie SG, Yang X, Im YH, Parks WT, Chen L, Zhou YX, Weinstein M, Kim SJ, Deng CX. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 19, 1868-1874 (2000). (Pubitemid 30219029)
74. Lüttges J, Galehdari H, Bröcker V, Schwarte-Waldhoff I, Henne-Bruns D, Klöppel G, Schmiegel W, Hahn SA. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis. Am. J. Pathol. 158, 1677-1683 (2001). (Pubitemid 32422932)
75. Howe JR, Roth S, Ringold JC, Summers RW, Järvinen HJ, Sistonen P, Tomlinson IP, Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280, 1086-1088 (1998). (Pubitemid 28234951)
76. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 92, 645-656 (1998). (Pubitemid 28141513)
77. Takaku K, Miyoshi H, Matsunaga A, Oshima M, Sasaki N, Taketo MM. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 9, 6113-6117 (1999). (Pubitemid 30035630)
78. Sirard C, Kim S, Mirtsos C, Tadich P, Hoodless PA, Itié A, Maxson R, Wrana JL, Mak TW. Targeted disruption in murine cells reveals variable requirement for Smad4 in transforming growth factor β-related signaling. J. Biol. Chem. 275, 2063-2070 (2000). (Pubitemid 30060834)
79. Dai JL, Schutte M, Bansal RK, Wilentz RE, Sugar AY, Kern SE. Transforming growth factor-beta responsiveness in DPC4/SMAD4-null cancer cells. Mol. Carcinog. 26, 37-43 (1999). (Pubitemid 29420184)
80. Fink SP, Swinler SE, Lutterbaugh JD, Massagué J, Thiagalingam S, Kinzler KW, Vogelstein B, Willson JK, Markowitz S.Transforming growth factor-β-induced growth inhibition in a Smad4 mutant colon adenoma cell line. Cancer Res. 61, 256-260 (2001). (Pubitemid 32109247)
81. Hocevar, B.A., Brown, T.L. & Howe, P.H. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 18, 1345-1356 (1999). (Pubitemid 29110318)
82. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK, Markowitz S. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 59, 320-324 (1999). (Pubitemid 29048861)
83. Iglesias, M., Frontelo, P., Gamallo, C. & Quintanilla, M. Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signaling pathway associated with progression to undifferentiated carcinomas. Oncogene 19, 4134-4145 (2000).
84. Martine Deckers, Maarten van Dinther, Jeroen Buijs, Ivo Que, Clemens Löwik, Gabri van der Pluijm and Peter ten Dijke. The Tumor Suppressor Smad4 Is Required for Transforming Growth Factor β-Induced Epithelial to Mesenchymal Transition and Bone Metastasis of Breast Cancer Cells. Cancer Res 66(4), 2202-9 (2006).
85. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68. (1980). (Pubitemid 10098769)
86. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 5, 591- 602. (2005). (Pubitemid 41081385)
87. Overall CM, Kleifeld O. Tumour microenvironment- opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6, 227-239(2006). (Pubitemid 43292566)
88. Eliza Wiercinska, Hildegonda P. H. Naber, Evangelia Pardali, Gabri van der Pluijm, Hans van Dam, Peter ten Dijke. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat. (2010).
89. Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama T, Utsunomiya J, Kuroki T, Mori T. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 18, 3098-3103 (1999). (Pubitemid 29261230)
90. Losi L, Bouzourene H, Benhattar J. Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep 17, 1095-1099 (2007).
91. Bixiang Zhang, Sunil K. Halder, Nilesh D. Kashikar, Yong-Jig Cho, Arunima Datta, D. Lee Gorden, Pran K. Datta. Antimetastatic role of Smad4 signaling in Colorectal Cancer. Gastroenterology 138, 969-980 (2010).
92. Roijer E, Moren A, ten Dijke P, Stenman G. Assignment of the Smad7 gene (MADH7) to human chromosome 18q21.1 by fluorescence in situ hybridization. Cytogenet Cell Genet 81, 189-90 (1998). (Pubitemid 28431938)
93. Boulay JL, Mild G, Reuter J, Lagrange M, Terracciano L, Lowy A, Laffer U, Orth B, Metzger U, Stamm B, Martinoli S, Herrmann R, Rochlitz C. Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7. Genes Chromosomes Cancer 31, 240-7(2001). (Pubitemid 32521754)
94. Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM, Kimura ET. Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. J Endocrinol Invest 26, 516-21(2003). (Pubitemid 36998699)
95. Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC, Janknecht R. Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol 96, 368-73 (2005). (Pubitemid 40127136)
96. Massague J. TGF-beta in cancer. Cell 134, 215-230 (2008).
97. Halder SK, Beauchamp RD and Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta induced growth inhibition and apoptosis. Exp Cell Res 307, 231- 246 (2005). (Pubitemid 40732749)
98. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Büchler MW, Falb D, Korc M. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18, 5363-5372 (1999). (Pubitemid 29469224)
99. Liu X, Lee J, Cooley M, Bhogte E, Hartley S and Glick A. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 63, 7760-7768 (2003). (Pubitemid 37466707)
100. Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM and Kimura ET. Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. J Endocrinol Invest 26, 516-521 (2003). (Pubitemid 36998699)
101. Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC and Janknecht R. Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol 96, 368-373 (2005). (Pubitemid 40127136)
102. Mikula M, Proell V, Fischer AN and Mikulits W. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 209, 560-567 (2006). (Pubitemid 44484647)
103. Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T, Sakamoto T, Kiyama S, Kiyama Y, Ubai T, Inamoto T, Takahara S, Itoh Y, Otsuki Y, Katsuoka Y, Miyazono K, Horie S. Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells. J Natl Cancer Inst 97, 1734-1746 (2005). (Pubitemid 41782283)
104. Fidler IJ. Blockade of the TGF-beta superfamily by Smad7 breaking a link in the metastatic chain. J Natl Cancer Inst 97, 1714-1715 (2005). (Pubitemid 41782276)
105. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA. TGFbeta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103, 197-206 (1999). (Pubitemid 29053137)
106. Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, André J, Delmas V, Larue L, Guise TA, Mauviel A. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 67, 2317-2324 (2007). (Pubitemid 46424252)
107. Javelaud D, Delmas V, Möller M, Sextius P, André J, Menashi S, Larue L, Mauviel A. Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 24, 7624- 7629(2005). (Pubitemid 41638037)
108. Halder SK, Rachakonda G, Deane NG, Datta PK. Smad7 induces hepatic metastasis in colorectal cancer. Br J Cancer. 99(6), 957-65 (2008).
109. Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, Rochlitz C. Amplification of SKI is a prognostic marker in early colorectal cancer. Neoplasia 6, 207- 12. (2004). (Pubitemid 38657076)
110. Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, Zhou Q. The Ski oncoprotein interacts with the Smad proteins to repress TGF-beta signaling. Genes Dev 13, 2196-206 (1999). (Pubitemid 29426725)
111. Shinagawa T, Dong HD, Xu M, Maekawa T, Ishii S. The sno gene, which encodes a component of the histone deacetylase complex, acts as a tumor suppressor in mice. EMBO J 19, 2280-91 (2000). (Pubitemid 30259009)
112. Shinagawa T, Nomura T, Colmenares C, Ohira M, Nakagawara A, Ishii S. Increased susceptibility to tumorigenesis of ski-deficient heterozygous mice. Oncogene 20, 8100-8 (2001). (Pubitemid 34028334)
113. Zhang F, Lundin M, Ristimäki A, Heikkilä P, Lundin J, Isola J, Joensuu H, Laiho M. Ski-related novel protein N (SkoN), a negative controller of transforming growth factor-b signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res 63, 5005- 10 (2003). (Pubitemid 37022638)
114. Reed JA, Bales E, XuW, Okan NA, Bandyopadhyay D, Medrano EE. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor b signaling. Cancer Res 61, 8074-8 (2001). (Pubitemid 33091592)
115. Medrano EE. Repression of TGF-beta signaling by the oncogenic protein SKI in human melanomas: consequences for proliferation, survival, and metastasis. Oncogene 22, 3123-9 (2003). (Pubitemid 36713764)
116. Poser I, Rothhammer T, Dooley S, Weiskirchen R, Bosserhoff AK. Characterization of Sno expression in malignant melanoma. Int J Oncol 26, 1411-7 (2005).
117. Fukuchi M, Nakajima M, Fukai Y, Miyazaki T, Masuda N, Sohda M, Manda R, Tsukada K, Kato H, Kuwano H. Increased expression of c-Ski as a co-repressor in transforming growth factor-b signaling correlates with progression of esophageal squamous cell carcinoma. Int J Cancer 108, 818-24 (2004). (Pubitemid 38112608)
118. Geyer CR, Colman-Lerner A, Brent R. "Mutagenesis" by peptide aptamers identifies genetic network members and pathway connections. Proc Natl Acad Sci USA 96, 8567-8572 (1999). (Pubitemid 29354832)
119. Cui Q, Lim SK, Zhao B, Hoffmann FM. Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene 24, 3864-3874 ( 2005). (Pubitemid 40896398)
120. Zhao BM, Hoffmann FM. Inhibition of Transforming Growth Factor-{beta}1-induced Signaling and Epithelial to Mesenchymal Transition by the Smad-binding Peptide Aptamer Trx-SARA. Mol Biol Cell 17, 3819-3831(2006). (Pubitemid 44330868)
121. Conery AR, Cao Y, Thompson EA, Townsend CM Jr, Ko TC, Luo K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis. Nature Cell Biology 6, 366-372 (2004). (Pubitemid 38584827)
122. Brown KA, Pietenpol JA, Moses HL. A Tale of Two Proteins: Differential Roles and Regulation of Smad2 and Smad3 in TGF-beta Signaling. Journal of Cellular Biochemistry 101, 9-33 (2007). (Pubitemid 46652569)
123. Wu JW, Hu M, Chai J, Seoane J, Huse M, Li C, Rigotti DJ, Kyin S, Muir TW, Fairman R, Massagué J, Shi Y. Crystal Structure of a Phosphorylated Smad2: Recognition of Phosphoserine by the MH2 Domain and Insights on Smad Function in TGF-beta Signaling. Molecular Cell 8, 1277- 1289 (2001). (Pubitemid 34084999)
124. Chai J, Wu JW, Yan N, Massagué J, Pavletich NP, Shi Y. Features of a Smad3 MH1-DNA Complex Roles Of Water And Zinc In DNA Binding. The Journal Of Biological Chemistry 278, 20327-20331. (2003). (Pubitemid 36799232)
125. Hart, P.J., Deep, S., Taylor, A.B., Shu, Z., Hinck, C.S., and Hinck, A.P. Crystal structure of the human TβR2 ectodomain-TGF-β3 complex. Nat. Struct. Biol. 9, 203- 208. (2002). (Pubitemid 34171313)